Want to see HK:1110 full AI Analyst Report?
1110 Stock Chart & Stats
HK$0.53
>-HK$0.01(-1.12%)
At close: 4:00 PM EST
HK$0.53
>-HK$0.01(-1.12%)
Day’s Range― - ―
52-Week RangeHK$0.33 - HK$0.78
Previous CloseN/A
Volume780.00K
Average Volume (3M)2.60M
Market Cap
HK$224.40M
Enterprise ValueHK$569.12
Total Cash (Recent Filing)HK$188.35M
Total Debt (Recent Filing)HK$438.04M
Price to Earnings (P/E)16.7
Beta0.36
Next Earnings
Mar 30, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield8.57%
Share Statistics
EPS (TTM)0.02
Shares Outstanding622,499,940
10 Day Avg. Volume1,885,600
30 Day Avg. Volume2,601,066
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)0.44
Price to Sales (P/S)0.30
P/FCF Ratio4.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Broad Healthcare Distribution ReachServing pharmacies, hospitals, and other healthcare distributors and retailers gives the company access to multiple downstream channels. This diversified route to market can support recurring product placement, broaden customer reach, and make the distribution platform more durable over the next several quarters.
Stable Gross MarginGross margin remaining in the mid-to-high 20% range recently indicates that underlying product economics have held up despite weaker reported earnings. This resilience can help preserve contribution per sale and provides a base for recovery if operating-cost pressure moderates.
Positive Recent Cash ConversionOperating cash flow stayed positive in 2025, and free cash flow represented roughly two-thirds of net income in 2024–2025. This shows reasonably effective conversion of accounting earnings into cash in the latest period, supporting operations and reducing reliance on external funding.
Bears Say
Revenue ContractionRevenue fell slightly in 2024 and more meaningfully in 2025 after stronger growth in 2021–2023. A sustained contraction would weaken operating scale, reduce channel leverage, and make it harder to absorb fixed costs, creating a durable challenge for restoring profitability.
Sharp Profitability DeteriorationNet margin dropped to about 1.2% in 2025 from 3.9% in 2024, while operating and EBITDA margins also declined. This compression leaves less profit from each sale, reduces internal funding capacity, and makes earnings more sensitive to cost or product-mix pressure.
Rising Leverage And Weaker ReturnsDebt-to-equity rising from about 0.39 to 0.70 signals a less conservative funding structure, while ROE falling to roughly 1.8% shows weaker returns on capital. Together, these trends reduce financial flexibility and could constrain investment or distributions if earnings remain soft.
Kingworld Medicines Group Ltd. News
1110 FAQ
What was Kingworld Medicines Group Ltd.’s price range in the past 12 months?
Kingworld Medicines Group Ltd. lowest stock price was HK$0.33 and its highest was HK$0.78 in the past 12 months.
What is Kingworld Medicines Group Ltd.’s market cap?
Kingworld Medicines Group Ltd.’s market cap is HK$224.40M.
When is Kingworld Medicines Group Ltd.’s upcoming earnings report date?
Kingworld Medicines Group Ltd.’s upcoming earnings report date is Mar 30, 2027 which is in 181 days.
How were Kingworld Medicines Group Ltd.’s earnings last quarter?
Kingworld Medicines Group Ltd. released its earnings results on Aug 27, 2026. The company reported -HK$0.01 earnings per share for the quarter.
Is Kingworld Medicines Group Ltd. overvalued?
According to Wall Street analysts Kingworld Medicines Group Ltd.’s price is currently Overvalued.
Does Kingworld Medicines Group Ltd. pay dividends?
Kingworld Medicines Group Ltd. pays a Annually dividend of HK$0.032 which represents an annual dividend yield of 8.57%. See more information on Kingworld Medicines Group Ltd. dividends here
What is Kingworld Medicines Group Ltd.’s EPS estimate?
Kingworld Medicines Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kingworld Medicines Group Ltd. have?
Kingworld Medicines Group Ltd. has 622,499,940 shares outstanding.
What happened to Kingworld Medicines Group Ltd.’s price movement after its last earnings report?
Kingworld Medicines Group Ltd. reported an EPS of -HK$0.01 in its last earnings report. Following the earnings report the stock price went up 1.176%.
Which hedge fund is a major shareholder of Kingworld Medicines Group Ltd.?
Currently, no hedge funds are holding shares in HK:1110
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kingworld Medicines Group Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.18%
12-Months-Change
Fundamentals
Return on Equity
8.57%
Trailing 12-Months
Asset Growth
-1.93%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Kingworld Medicines Group Ltd.
Kingworld Medicines Group Limited functions as an investment holding company primarily engaged in the distribution of imported, branded pharmaceutical and healthcare items. The company also supplies a range of medical products, health goods, and general food items. Its extensive product catalog caters to various therapeutic areas, such as respiratory relief (for cough and phlegm), gastrointestinal issues, vitamin supplementation, orthopedic support, cardiovascular health, and influenza care. Key brands distributed include Nin Jiom Chuan Bei Pei Pa Koa, Taiko Seirogan, the Kawai Product Range, Flying Eagle Wood Lok Medicated Oil, Kyushin Pill, and the Mentholatum Product Range. Furthermore, Kingworld is involved in the production and sale of electrotherapeutic and physiotherapeutic devices, as well as common medical examination equipment. Its market presence spans the People's Republic of China, Hong Kong, the United States, the United Kingdom, Germany, Italy, Spain, Mexico, and other international regions. The company, founded in 1996, is headquartered in Shenzhen, PRC.
Technical Analysis
Extrawell Pharmaceutical Holdings Limited
―
Tianda Pharmaceuticals Ltd.
―
Wai Yuen Tong Medicine Holdings Limited
―
PuraPharm Corp. Ltd.
―
Pak Fah Yeow International Limited
―